Bill Ackman’s VRX/AGN Presentation

Updated on

Bill Ackman’s presentation on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Allergan, Inc. (NYSE:AGN) is reproduced below.  Pershing Square hedge fund manager Bill Ackman and Valeant Pharmaceuticals CEO Mike Pearson gave a highly-entertaining and informative talk about the acquisition of botox-maker Allergan, but the meat of the argument is contained in Pershing Square’s presentation.

Weighing in at 110 pages, the presentation doesn’t skimp on details.  Covering a wide range of subjects, the paper blasts the current pharma R&D model as “high risk, low reward,” calling it “broken,” while holding up Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) as an example of a company that breaks the mold with “focused, productive” R&D spending.

The presentation sings the praises of Valeant, noting its “culture of cost efficiency” and its “core competency in licensing and acquisitions.”

See Bill Ackman’s VRX/AGN Presentation in PDF format here.

Bill Ackman’s VRX/AGN Presentation by ValueWalk

Leave a Comment

Signup to ValueWalk!

Get the latest posts on what's happening in the hedge fund and investing world sent straight to your inbox! 
This is information you won't get anywhere else!